...
首页> 外文期刊>Clinical and experimental ophthalmology >Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
【24h】

Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.

机译:玻璃体视网膜疾病患者玻璃体内纤溶系统的成分。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To assess components of the fibrinolytic system in the vitreous humour and serum of patients with vitreoretinal disorders. METHODS: Forty-three samples of vitreous humour and plasma of 43 patients undergoing pars plana vitrectomy for macular hole, macular pucker, retinal detachment or proliferative vitreoretinopathy were evaluated for their content of plasminogen, a2-antiplasmin, plasminogen-activatorinhibitor 1, plasmin-a2-antiplasmin-complex, tissue plasminogen activator, total protein, albumin, d-dimer. Patient groups were compared with each other using the U-test (Mann and Whitney) for non-parametric testing of two independent samples. RESULTS: The groups of retinal detachment and proliferative vitreoretinopathy had elevated vitreal levels of plasminogenactivator-inhibitor 1 (352.5 and 370.7 ng/mL vs. 1.86 and 56.6 ng/mL, P = non-significant), plasmin-a2-antiplasmincomplex (2416.5 and 1836.2 microg/L vs. 124.2 and 133.4 microg/L, P < 0.001), albumin (0.08 and 0.15 g/dL vs. 0.03 and 0.07 g/dL, P < 0.05) and d-dimer (4.76 and 1.64 microg/mL vs. 0.40 and 0.48 microg/mL, P = non-significant) when compared with patients with macular hole and macular pucker. CONCLUSIONS: There are significant differences in the vitreal concentration of components of the fibrinolytic system in patients with vitreoretinal disorders. Breakdown of the blood-retinal barrier and complex disease-specific mechanisms are thought to be responsible for an increase of components of the fibrinolytic system in the vitreous.
机译:目的:评估玻璃体视网膜疾病患者的玻璃体液和血清中的纤溶系统成分。方法:对43例行黄斑裂孔,黄斑皱纹,视网膜脱离或增生性玻璃体视网膜病变的玻璃体玻璃体切除术的43例患者的玻璃体液和血浆样本中的纤溶酶原,a2-抗纤溶酶,纤溶酶原激活物抑制剂1,纤溶酶a2的含量进行了评估。 -抗纤溶酶复合物,组织纤溶酶原激活物,总蛋白,白蛋白,d-二聚体。使用U检验(Mann和Whitney)将患者组彼此进行比较,以对两个独立样本进行非参数测试。结果:视网膜脱离和增生性玻璃体视网膜病变组的纤溶酶原激活物抑制剂1的玻璃体水平升高(分别为352.5和370.7 ng / mL,而1.86和56.6 ng / mL,P =无显着性),纤溶酶-a2-抗血浆复合物(2416.5和1836.2 microg / L对比124.2和133.4 microg / L,P <0.001),白蛋白(0.08和0.15 g / dL vs.0.03和0.07 g / dL,P <0.05)和d-二聚体(4.76和1.64 microg / mL与有黄斑裂孔和黄斑皱褶的患者相比,分别为0.40和0.48 microg / mL,P =无显着性)。结论:玻璃体视网膜疾病患者的纤溶系统成分的玻璃体浓度存在显着差异。血视网膜屏障的破坏和复杂的疾病特异性机制被认为是玻璃体纤维蛋白溶解系统组分增加的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号